{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T07:17:20Z","timestamp":1770707840827,"version":"3.49.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T00:00:00Z","timestamp":1563926400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T00:00:00Z","timestamp":1563926400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Sanofi Aventis Deutschland GmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s00592-019-01383-w","type":"journal-article","created":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T11:07:12Z","timestamp":1563966432000},"page":"89-99","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Titration of insulin glargine 100\u00a0U\/mL when added to oral antidiabetic drugs in patients with type 2 diabetes: results of the TOP-1 real-world study"],"prefix":"10.1007","volume":"57","author":[{"given":"Stefan","family":"Pscherer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helmut","family":"Anderten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Pfohl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Fritsche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja","family":"Borck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrin","family":"Pegelow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4970-2110","authenticated-orcid":false,"given":"Peter","family":"Bramlage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jochen","family":"Seufert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,24]]},"reference":[{"key":"1383_CR1","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1056\/NEJMoa075392","volume":"357","author":"RR Holman","year":"2007","unstructured":"Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S et al (2007) Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 357:1716\u20131730. \nhttps:\/\/doi.org\/10.1056\/NEJMoa075392","journal-title":"N Engl J Med"},{"key":"1383_CR2","doi-asserted-by":"publisher","first-page":"254","DOI":"10.2337\/diacare.28.2.254","volume":"28","author":"HU Janka","year":"2005","unstructured":"Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Jarvinen H (2005) Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 28:254\u2013259. \nhttps:\/\/doi.org\/10.2337\/diacare.28.2.254","journal-title":"Diabetes Care"},{"key":"1383_CR3","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/S0140-6736(08)60485-7","volume":"371","author":"RG Bretzel","year":"2008","unstructured":"Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C, Linn T (2008) Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 371:1073\u20131084. \nhttps:\/\/doi.org\/10.1016\/S0140-6736(08)60485-7","journal-title":"Lancet"},{"key":"1383_CR4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.4158\/CS-2017-0153","volume":"24","author":"AJ Garber","year":"2018","unstructured":"Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA et al (2018) Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2018 executive summary. Endocr Pract 24:91\u2013120. \nhttps:\/\/doi.org\/10.4158\/CS-2017-0153","journal-title":"Endocr Pract"},{"key":"1383_CR5","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1111\/dom.12886","volume":"19","author":"L Ji","year":"2017","unstructured":"Ji L, Zhang P, Zhu D, Li X, Ji J, Lu J et al (2017) Observational registry of basal insulin treatment (ORBIT) in patients with type 2 diabetes uncontrolled with oral antihyperglycaemic drugs: real-life use of basal insulin in China. Diabetes Obes Metab 19:822\u2013830. \nhttps:\/\/doi.org\/10.1111\/dom.12886","journal-title":"Diabetes Obes Metab"},{"key":"1383_CR6","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s00125-012-2534-0","volume":"55","author":"SE Inzucchi","year":"2012","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M et al (2012) Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55:1577\u20131596. \nhttps:\/\/doi.org\/10.1007\/s00125-012-2534-0","journal-title":"Diabetologia"},{"key":"1383_CR7","doi-asserted-by":"publisher","first-page":"140","DOI":"10.2337\/dc14-2441","volume":"38","author":"SE Inzucchi","year":"2015","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M et al (2015) Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 38:140\u2013149. \nhttps:\/\/doi.org\/10.2337\/dc14-2441","journal-title":"Diabetes Care"},{"key":"1383_CR8","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/1753-0407.12080","volume":"6","author":"G Dailey","year":"2014","unstructured":"Dailey G, Aurand L, Stewart J, Ameer B, Zhou R (2014) Comparison of three algorithms for initiation and titration of insulin glargine in insulin-naive patients with type 2 diabetes mellitus. J Diabetes 6:176\u2013183. \nhttps:\/\/doi.org\/10.1111\/1753-0407.12080","journal-title":"J Diabetes"},{"key":"1383_CR9","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.2337\/diacare.28.6.1282","volume":"28","author":"Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R, Group AS","year":"2005","unstructured":"Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R, Group AS (2005) Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care 28:1282\u20131288. \nhttps:\/\/doi.org\/10.2337\/diacare.28.6.1282","journal-title":"Diabetes Care"},{"key":"1383_CR10","doi-asserted-by":"publisher","first-page":"952","DOI":"10.7326\/0003-4819-138-12-200306170-00006","volume":"138","author":"Fritsche A, Schweitzer MA, Haring HU, Study G","year":"2003","unstructured":"Fritsche A, Schweitzer MA, Haring HU, Study G (2003) Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 138:952\u2013959. \nhttps:\/\/doi.org\/10.7326\/0003-4819-138-12-200306170-00006","journal-title":"Ann Intern Med"},{"key":"1383_CR11","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.clinthera.2014.06.032","volume":"36","author":"X Li","year":"2014","unstructured":"Li X, Du T, Li W, Zhang T, Liu H, Xiong Y (2014) Efficacy and safety of weight-based insulin glargine dose titration regimen compared with glucose level- and current dose-based regimens in hospitalized patients with type 2 diabetes: a randomized, controlled study. Clin Ther 36:1269\u20131275. \nhttps:\/\/doi.org\/10.1016\/j.clinthera.2014.06.032","journal-title":"Clin Ther"},{"key":"1383_CR12","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1177\/193229680700100412","volume":"1","author":"P Strange","year":"2007","unstructured":"Strange P (2007) Treat-to-target insulin titration algorithms when initiating long or intermediate acting insulin in type 2 diabetes. J Diabetes Sci Technol 1:540\u2013548. \nhttps:\/\/doi.org\/10.1177\/193229680700100412","journal-title":"J Diabetes Sci Technol"},{"key":"1383_CR13","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1111\/j.1463-1326.2010.01239.x","volume":"12","author":"V Owen","year":"2010","unstructured":"Owen V, Seetho I, Idris I (2010) Predictors of responders to insulin therapy at 1\u00a0year among adults with type 2 diabetes. Diabetes Obes Metab 12:865\u2013870. \nhttps:\/\/doi.org\/10.1111\/j.1463-1326.2010.01239.x","journal-title":"Diabetes Obes Metab"},{"key":"1383_CR14","unstructured":"Sinclair A, Dunning T, Colagiuri S, Jacqmain O (2013) IDF global guideline for managing older people with type 2 diabetes. International Diabetes Federation. \nhttps:\/\/www.idf.org\/e-library\/guidelines\/78-global-guideline-for-managing-older-people-with-type-2-diabetes.html\n\n. Accessed 17 July 2019"},{"key":"1383_CR15","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/dom.13535","volume":"21","author":"J Seufert","year":"2019","unstructured":"Seufert J, Fritsche A, Pscherer S, Anderten H, Borck A, Pegelow K et al (2019) Titration and optimization trial for the initiation of insulin glargine 100\u00a0U\/mL in patients with inadequately controlled type 2 diabetes on oral antidiabetic drugs. Diabetes Obes Metab 21:439\u2013443. \nhttps:\/\/doi.org\/10.1111\/dom.13535","journal-title":"Diabetes Obes Metab"},{"key":"1383_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13768","author":"M Pfohl","year":"2019","unstructured":"Pfohl M, Pscherer S, Fritsche A, Anderten H, Borck A, Pegelow K et al (2019) Predictors of treatment response in type-2 diabetes patients initiating basal-supported oral therapy with insulin glargine 100 U\/mL - a sub-analysis of the Titration and OPtimisation (TOP) registry. Diabetes Obes Metab. \nhttps:\/\/doi.org\/10.1111\/dom.13768","journal-title":"Diabetes Obes Metab"},{"key":"1383_CR17","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1046\/j.1464-5491.2002.00764.x","volume":"19","author":"E Bonora","year":"2002","unstructured":"Bonora E, Targher G, Alberiche M, Formentini G, Calcaterra F, Lombardi S et al (2002) Predictors of insulin sensitivity in Type 2 diabetes mellitus. Diabet Med 19:535\u2013542. \nhttps:\/\/doi.org\/10.1046\/j.1464-5491.2002.00764.x","journal-title":"Diabet Med"},{"key":"1383_CR18","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s13300-016-0153-3","volume":"7","author":"M Hanefeld","year":"2016","unstructured":"Hanefeld M, Monnier L, Schnell O, Owens D (2016) Early treatment with basal insulin glargine in people with type 2 diabetes: lessons from ORIGIN and other cardiovascular trials. Diabetes Ther 7:187\u2013201. \nhttps:\/\/doi.org\/10.1007\/s13300-016-0153-3","journal-title":"Diabetes Ther"},{"key":"1383_CR19","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.2337\/dc06-1357","volume":"30","author":"H Yki-Jarvinen","year":"2007","unstructured":"Yki-Jarvinen H, Juurinen L, Alvarsson M, Bystedt T, Caldwell I, Davies M et al (2007) Initiate insulin by aggressive titration and education (INITIATE): a randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. Diabetes Care 30:1364\u20131369. \nhttps:\/\/doi.org\/10.2337\/dc06-1357","journal-title":"Diabetes Care"},{"key":"1383_CR20","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1111\/j.1464-5491.2006.01881.x","volume":"23","author":"HC Gerstein","year":"2006","unstructured":"Gerstein HC, Yale JF, Harris SB, Issa M, Stewart JA, Dempsey E (2006) A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and\/or sulphonylureas. The Canadian INSIGHT (implementing new strategies with insulin glargine for hyperglycaemia treatment) study. Diabet Med 23:736\u2013742. \nhttps:\/\/doi.org\/10.1111\/j.1464-5491.2006.01881.x","journal-title":"Diabet Med"},{"key":"1383_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2337\/diacare.29.01.06.dc05-1058","volume":"29","author":"L Kennedy","year":"2006","unstructured":"Kennedy L, Herman WH, Strange P, Harris A, Team GA (2006) Impact of active versus usual algorithmic titration of basal insulin and point-of-care versus laboratory measurement of HbA1c on glycemic control in patients with type 2 diabetes: the glycemic optimization with algorithms and labs at point of care (GOAL A1C) trial. Diabetes Care 29:1\u20138. \nhttps:\/\/doi.org\/10.2337\/diacare.29.01.06.dc05-1058","journal-title":"Diabetes Care"},{"key":"1383_CR22","doi-asserted-by":"publisher","first-page":"554","DOI":"10.2337\/diacare.29.03.06.dc05-0695","volume":"29","author":"J Rosenstock","year":"2006","unstructured":"Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G (2006) Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care 29:554\u2013559. \nhttps:\/\/doi.org\/10.2337\/diacare.29.03.06.dc05-0695","journal-title":"Diabetes Care"},{"key":"1383_CR23","doi-asserted-by":"publisher","first-page":"711","DOI":"10.2147\/VHRM.S54362","volume":"9","author":"J Seufert","year":"2013","unstructured":"Seufert J, Pegelow K, Bramlage P (2013) Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study. Vasc Health Risk Manag 9:711\u2013717. \nhttps:\/\/doi.org\/10.2147\/VHRM.S54362","journal-title":"Vasc Health Risk Manag"},{"key":"1383_CR24","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1177\/1932296814566232","volume":"9","author":"H Anderten","year":"2015","unstructured":"Anderten H, Dippel FW, Kostev K (2015) Early discontinuation and related treatment costs after initiation of Basal insulin in type 2 diabetes patients: a German primary care database analysis. J Diabetes Sci Technol 9:644\u2013650. \nhttps:\/\/doi.org\/10.1177\/1932296814566232","journal-title":"J Diabetes Sci Technol"},{"issue":"1658\u20131670","key":"1383_CR25","doi-asserted-by":"publisher","first-page":"e1656","DOI":"10.1016\/j.clinthera.2017.06.011","volume":"39","author":"R Mahabaleshwarkar","year":"2017","unstructured":"Mahabaleshwarkar R, Gohs F, Mulder H, Wilkins N, DeSantis A, Anderson WE et al (2017) Patient and provider factors affecting clinical inertia in patients with Type 2 diabetes on metformin monotherapy. Clin Ther 39(1658\u20131670):e1656. \nhttps:\/\/doi.org\/10.1016\/j.clinthera.2017.06.011","journal-title":"Clin Ther"},{"key":"1383_CR26","doi-asserted-by":"publisher","first-page":"151","DOI":"10.4158\/EP15868.OR","volume":"22","author":"J Lin","year":"2016","unstructured":"Lin J, Zhou S, Wei W, Pan C, Lingohr-Smith M, Levin P (2016) Does clinical inertia vary by personalized A1c goal? A study of predictors and prevalence of clinical inertia in a U.S. Managed-Care Setting. Endocr Pract 22:151\u2013161. \nhttps:\/\/doi.org\/10.4158\/EP15868.OR","journal-title":"Endocr Pract"},{"key":"1383_CR27","doi-asserted-by":"publisher","first-page":"971","DOI":"10.2337\/dc08-1911","volume":"32","author":"LN McEwen","year":"2009","unstructured":"McEwen LN, Bilik D, Johnson SL, Halter JB, Karter AJ, Mangione CM et al (2009) Predictors and impact of intensification of antihyperglycemic therapy in type 2 diabetes: translating research into action for diabetes (TRIAD). Diabetes Care 32:971\u2013976. \nhttps:\/\/doi.org\/10.2337\/dc08-1911","journal-title":"Diabetes Care"},{"key":"1383_CR28","doi-asserted-by":"publisher","first-page":"403","DOI":"10.12659\/MSM.892248","volume":"21","author":"V Bralic Lang","year":"2015","unstructured":"Bralic Lang V, Bergman Markovic B, Kranjcevic K (2015) Family physician clinical inertia in glycemic control among patients with type 2 diabetes. Med Sci Monit 21:403\u2013411. \nhttps:\/\/doi.org\/10.12659\/MSM.892248","journal-title":"Med Sci Monit"},{"key":"1383_CR29","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3810\/pgm.2014.10.2824","volume":"126","author":"CF Shaefer","year":"2014","unstructured":"Shaefer CF, Reid TS, Dailey G, Mabrey ME, Vlajnic A, Stuhr A et al (2014) Weight change in patients with type 2 diabetes starting basal insulin therapy: correlates and impact on outcomes. Postgrad Med 126:93\u2013105. \nhttps:\/\/doi.org\/10.3810\/pgm.2014.10.2824","journal-title":"Postgrad Med"},{"key":"1383_CR30","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/dom.12438","volume":"17","author":"GB Bolli","year":"2015","unstructured":"Bolli GB, Riddle MC, Bergenstal RM, Ziemen M, Sestakauskas K, Goyeau H et al (2015) New insulin glargine 300\u00a0U\/ml compared with glargine 100\u00a0U\/ml in insulin-naive people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes Metab 17:386\u2013394. \nhttps:\/\/doi.org\/10.1111\/dom.12438","journal-title":"Diabetes Obes Metab"},{"key":"1383_CR31","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1111\/dom.12532","volume":"17","author":"H Yki-Jarvinen","year":"2015","unstructured":"Yki-Jarvinen H, Bergenstal RM, Bolli GB, Ziemen M, Wardecki M, Muehlen-Bartmer I et al (2015) Glycaemic control and hypoglycaemia with new insulin glargine 300\u00a0U\/ml versus insulin glargine 100\u00a0U\/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension. Diabetes Obes Metab 17:1142\u20131149. \nhttps:\/\/doi.org\/10.1111\/dom.12532","journal-title":"Diabetes Obes Metab"},{"key":"1383_CR32","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/dom.12485","volume":"17","author":"R Ritzel","year":"2015","unstructured":"Ritzel R, Roussel R, Bolli GB, Vinet L, Brulle-Wohlhueter C, Glezer S et al (2015) Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300\u00a0U\/ml versus glargine 100\u00a0U\/ml in people with type 2 diabetes. Diabetes Obes Metab 17:859\u2013867. \nhttps:\/\/doi.org\/10.1111\/dom.12485","journal-title":"Diabetes Obes Metab"},{"key":"1383_CR33","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1111\/dom.12472","volume":"17","author":"MC Riddle","year":"2015","unstructured":"Riddle MC, Yki-Jarvinen H, Bolli GB, Ziemen M, Muehlen-Bartmer I, Cissokho S et al (2015) One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300\u00a0U\/ml compared with 100\u00a0U\/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension. Diabetes Obes Metab 17:835\u2013842. \nhttps:\/\/doi.org\/10.1111\/dom.12472","journal-title":"Diabetes Obes Metab"}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-019-01383-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00592-019-01383-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-019-01383-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T23:27:55Z","timestamp":1595460475000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00592-019-01383-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,24]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["1383"],"URL":"https:\/\/doi.org\/10.1007\/s00592-019-01383-w","relation":{},"ISSN":["0940-5429","1432-5233"],"issn-type":[{"value":"0940-5429","type":"print"},{"value":"1432-5233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,24]]},"assertion":[{"value":"5 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"AF: Member of Scientific Advisory Boards of Sanofi, Novo Nordisk, Lilly, and Boehringer. HA: Honorary for consultancy: Sanofi, MSD, Lilli, Boehringer Ingelheim, and Pfizer. MP: Honorary for talks: B. Braun, Fresenius, Eli Lilly, Novartis, Novo Nordisk, and Sanofi. Honorary for consultancy: Boehringer Ingelheim, Eli Lilly, Novo Nordisk and Sanofi. SP: Member of Scientific Advisory Boards of Sanofi. Honorary for talks: Eli Lilly, Novartis, Novo Nordisk, MSD, and Sanofi. AB and KP are employees of Sanofi. PB: Honorary for consultancy: Sanofi-Aventis, MSD, AstraZeneca, Bristol Myers Squibb (BMS), Boehringer Ingelheim, Novartis, Pfizer. JS received honoraria for talks and\/or consultancy and\/or research funding from Apitope, Astra Zeneca, Bayer, Berlin Chemie, Boehringer Ingelheim, Bristol Myers Squibb (BMS), GI-Dynamics, Glaxo Smith Kline (GSK), Intarcia, Ipsen, Janssen, LifeScan, Lilly, Merck Sharp Dohme (MSD), MedScape, Novartis, NovoNordisk, Omniamed, Pfizer, Roche, Sanofi Aventis, Servier, Takeda, and Ypsomed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee (Freiburg University Ethics Committee, 241\/13) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}